Evidence map›Paper›PMID 31242923›Full record

ReviewPediatric rheumatology online journal2019

Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist.

Jennifer J Y Lee, Alhanouf Alsaleem, Grace P K Chiang, Elizaveta Limenis, Watchareewan Sontichai, Rae S M Yeung, Jonathan Akikusa, Ronald M Laxer

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatric rheumatology online journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 20 citations in OpenAlex.

  1. Childhood Vasculitis.Indian journal of pediatrics · 2024
    Review
  2. Use of rituximab in paediatric nephrology.Archives of disease in childhood · 2021
    Review
  3. Recent Advances in Pediatric Vasculitis.Rheumatic diseases clinics of North America · 2021
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Jennifer J Y LeeDepartment of Pediatrics, Division of Rheumatology, Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.
Alhanouf AlsaleemDepartment of Pediatrics, Division of Rheumatology, Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.
Grace P K ChiangDepartment of Pediatrics, Division of Rheumatology, Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.
Elizaveta LimenisDepartment of Pediatrics, Division of Rheumatology, Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.
Watchareewan SontichaiDepartment of Pediatrics, Division of Rheumatology, Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.
Rae S M YeungDepartment of Pediatrics, Division of Rheumatology, Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.
Jonathan AkikusaDepartment of Rheumatology, The Royal Children's Hospital, Melbourne, Australia.
Ronald M LaxerDepartment of Pediatrics, Division of Rheumatology, Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. ronald.laxer@sickkids.ca.
University of Toronto · CAHospital for Sick Children · CARoyal Children's Hospital · AUSickKids Foundation · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) refers to a complex group of systemic vasculitides that are characterized by primary small-to-medium sized blood vessel inflammation with the presence of autoantibodies known as ANCA. AAV diseases include Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), and Microscopic Polyangiitis (MPA). AAVs are challenging conditions associated with high cumulative disease and treatment related morbidity and mortality. Given its rarity and the resulting paucity of pediatric-specific clinical trial evidence, pediatric rheumatologists have had to often extrapolate from adult literature for management and therapeutic decisions. The aim of this review is to provide a comprehensive overview of the important findings and overall conclusions of critical landmark clinical trials in the induction and maintenance treatments in adult AAV for the pediatric rheumatologist. This review also highlights the outcomes of recent pediatric AAV observational studies and discusses the future research priorities in pediatric AAV management.

Indexed as

AdultAnti-Inflammatory AgentsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAzathioprineChildChurg-Strauss SyndromeCyclophosphamideDrug SubstitutionDrug Therapy, CombinationForecastingGlucocorticoidsGranulomatosis with PolyangiitisHumansLeflunomideMethotrexateMycophenolic AcidAnti-Inflammatory AgentsAzathioprineCyclophosphamideGlucocorticoidsLeflunomideMethotrexateMycophenolic AcidPrednisoneRituximabAnti-neutrophil cytoplasmic antibody-associated VasculitisManagementPediatricVasculitis

Identifiers

PMID31242923
PMCPMC6595671
OpenAlexW2953624779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.